This browser is not actively supported anymore. For the best passle experience, we strongly recommend you upgrade your browser.
Skip to main content
United Kingdom | EN-GB

Add a bookmark to get started

Cortex - Life Sciences Insights

| 4 minutes read

China’s Revised Regulations on Medical Devices: Good News for Industry Stakeholders?

On 9 February 2021, the PRC State Council issued the revised PRC Regulations on the Supervision and Administration of Medical Devices (the “Revised Medical Device Regulations”), which will become effective on 1 June 2021. The Revised Medical Device Regulations is the third revision of the regulations since they were initially promulgated in 2000 (the first and second revisions occurring in year 2014 and 2017, respectively) and incorporates significant changes to the current regulatory framework for medical devices.

The Revised Medical Device Regulations have incorporated and further developed the reforms for marketing approval of medical devices undertaken by the National Medical Products Administration (“NMPA”) in recent years.  The revised regulations have also taken into consideration the prevalent international practice for regulations of medical devices, which shows China’s desire to be aligned with other innovative jurisdictions in this industry.  The major changes of the Revised Medical Device Regulations, generally all positive for industry stakeholders, include the following:

  • implementing a marketing authorization holder (“MAH”) regime;
  • encouraging medical device innovations;
  • expediting the regulatory review and approval process; and
  • strengthening administrative penalties for illegal conduct.

We describe these changes in further detail below:

1. Implementation of a MAH regime

Similar to the MAH regime for drugs, the Revised Medical Device Regulations implement a MAH regime for medical devices, which allows research institutions and companies that do not possess manufacturing capability to be the MAH.  This reform incentivizes research institutions and companies which do not possess manufacturing capability to develop innovative medical device products, and, importantly, provides such entities with ownership and control of marketing approval in China.  However, it is important to note that the MAH will be responsible for the safety and effectiveness of the product for its entire lifecycle.  Specifically, the MAH will be responsible for the legality, authenticity, accuracy, completeness and traceability of the materials and data submitted for product registration or recordal.  The MAH is also responsible for product quality control, post-market-approval study and risk control, adverse event monitoring and re-evaluation, product tracking and recall.   Overseas entities can be MAHs, but they need to designate a PRC enterprise to assist them in fulfilling the aforementioned obligations.  The establishment of the MAH regime is an example of China’s effort to align with the recognized international practice.

2. Supporting and encouraging medical device innovations

Another theme throughout the Revised Medical Device Regulations is its emphasis on medical device innovations.  According to the newly-added provisions of the Revised Medical Device Regulations, the government will promulgate a medical device industry plan and policies to promote medical device innovation.  Innovative medical device products will not only enjoy prioritized review and examination for market access but also gain support for post-market promotion and clinical use, such as support during the government’s bidding and procurement process.

The Revised Medical Device Regulation also encourages and facilitates the import of foreign innovative medical devices. Specifically, the Revised Medical Device Regulations exempt the requirement of a pre-existing market authorization for registering or recording an imported medical device product.  An implication of  this reform is that a global company can simultaneously apply for market access of its innovative product at least in the country of origin and in China, one of the largest market in the world.

3. Expediting the regulatory review and approval process

The Revised Medical Device Regulations officially establish the following expedited approval pathways:

(1) A prioritized review and approval pathway for innovative medical devices;

(2) A conditional approval pathway for urgently needed medical devices that are used to treat orphan diseases or severely life-threatening diseases without effective treatments, or are used to respond to public health incidents;

(3) An emergency use approval pathway for the emergency use of medical devices within a defined scope and a defined period, e.g., COVID-19 testing kits approved under this pathway during the COVID-19 pandemic; and

(4) A sympathetic use approval pathway for extending the use of medical devices that are undergoing clinical trials for the treatment of severely life-threatening diseases without effective treatments to other patients with the same condition in the same trial institution under certain circumstances.

On 26 March 2021, NMPA issued the Draft for Soliciting Public Opinions on the Administrative Measures for Medical Device Registration, which further elaborates on the aforementioned approval pathways.  Comments on the draft should be submitted to NMPA by April 25, 2021. 

4. Strengthening the administrative penalties for illegal conduct

Similar to the recently amended PRC Drug Administration Law, the Revised Medical Device Regulations have not only increased the penalty for violations but also introduced personal liability for key players of the violating companies.  For example, with regard to manufacturing and/or operating unregistered medical devices in China, the maximum fine is raised from RMB 100,000 to RMB 150,000 where the total value of goods is less than RMB 10,000, and the maximum fine is raised from 20 times the value of goods to 30 times the value of goods where the total value of goods exceeds RMB 10,000.  For so-called “serious violations,” the legal representative, principal or directly-responsible person in charge and other responsible personnel of the company shall incur personal liabilities, including confiscation of all income from the company during the period of illegal conduct, a fine of 30% to 3 times of the aforementioned income, and being permanently barred from engaging in medical device manufacturing and/or operations.

The above revisions on administrative penalties are not surprising as China has been clamping down on regulatory violations in the medical device sector for the past few years, and strengthened enforcement and increased penalties have been a trend in the regulation of drugs and medical devices.

In general, the Revised Medical Device Regulations are a welcome change to the pre-existing regime.  We anticipate that the ancillary rules and regulations governing medical devices in China, such as the medical device registration measures, the medical device production measures and the medical device operation measures, will be revised in a similar fashion to clarify and implement the changes introduced by the Revised Medical Device Regulations, and we will keep you updated of any significant developments.


regulation-devices, china